Thalassemia, Beta Clinical Trial
Official title:
Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05799118 -
Study of the Role of Genetic Modifiers in Hemoglobinopathies
|
||
| Completed |
NCT06153784 -
Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT05132270 -
Clinical Experience of Thalidomide in Thalassemic Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736419 -
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
|
Phase 2 | |
| Recruiting |
NCT06314529 -
Long-term Follow-up Study of BHC001 for TDT
|
||
| Recruiting |
NCT06041620 -
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
|
N/A | |
| Recruiting |
NCT03183375 -
The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan
|
Phase 2 |